Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Updates on Endometrial Cancer Screening and Treatment
share announcement

Updates on Endometrial Cancer Screening and Treatment

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: closed (30 July 2024) | Viewed by 8327

Special Issue Editors

Dr. Dimitrios Papageorgiou

E-Mail Website
Guest Editor
Department of Gynecology, Athens Naval and Veteran Hospital, 11521 Athens, Greece
Interests: minimally invasive gynecology; gynecology; endometriosis; gynecologic malignancies; HIPEC; obstetrics; high risk pregnancies
Special Issues, Collections and Topics in MDPI journals
Dr. Dimitrios-Efthymios Vlachos

E-Mail Website
Guest Editor
1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, 10679 Athens, Greece
Interests: gynecology; endometrial cancer

Special Issue Information

Dear Colleagues,

Endometrial cancer is a type of cancer that originates in the inner lining of the uterus, known as the endometrium. It is the most common gynecologic cancer in developed countries and primarily affects postmenopausal women, although it can occur in premenopausal women as well. In 2020, 417,367 new cases of endometrial cancer were registered, with up to 14% of them were in patients of reproductive age. Endometrial cancer often presents with noticeable symptoms, prompting women to seek medical attention. The most common symptom is abnormal vaginal bleeding, particularly postmenopausal bleeding. Other symptoms may include pelvic pain, pain during intercourse and unexplained weight loss.

Endometrial cancer is a heterogeneous disease with multiple etiological factors contributing to its development. The most prominent risk factor is a hormonal imbalance, specifically an increased exposure to estrogen unopposed by progesterone. This hormonal imbalance can result from various conditions, including obesity, metabolic syndrome and hormone replacement therapy. Nulliparity, early menarche, late menopause, tamoxifen use, older age and Lynch syndrome are also among the risk factors. Understanding the molecular mechanisms underlying endometrial cancer development, such as alterations in the PTEN/PI3K/Akt pathway and DNA mismatch repair genes, is essential for targeted therapeutic interventions and estimating the risk of recurrence and survival.

In this Special Issue, we present an update regarding the diagnosis and screening of endometrial cancer, the role of molecular features of endometrial carcinoma in overall survival and the latest data concerning treatment options.

We are pleased to invite authors to submit manuscripts focusing on the screening, diagnosis, management and treatment of endometrial cancer, and we are soliciting original studies, meta-analysis, reviews and case report investigating new advances in endometrial cancer treatment.

Dr. Dimitrios Papageorgiou
Dr. Dimitrios-Efthymios Vlachos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • endometrial intraepithelial neoplasia
  • microsatellite instability
  • mismatch repair
  • hysterectomy
  • chemotherapy
  • radiation therapy
  • hormonal therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 1779 KiB  
Article
External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center
by Dimitrios Tsolakidis, Dimitrios Zouzoulas, Iliana Sofianou, Tilemaxos Karalis, Kimon Chatzistamatiou, Vasilis Theodoulidis, Maria Topalidou, Eleni Timotheadou and Grigoris Grimbizis
Medicina 2024, 60(9), 1421; https://doi.org/10.3390/medicina60091421 - 30 Aug 2024
Cited by 2 | Viewed by 3567
Abstract
Background and Objectives: The new molecular classification of endometrial cancer continuously changes the management of the disease in everyday clinical practice. Recently, FIGO released a new staging system for endometrial cancer, which incorporates molecular substages and subdivides further early-stage disease. The aim [...] Read more.
Background and Objectives: The new molecular classification of endometrial cancer continuously changes the management of the disease in everyday clinical practice. Recently, FIGO released a new staging system for endometrial cancer, which incorporates molecular substages and subdivides further early-stage disease. The aim of this study was to investigate the differences between the two FIGO staging systems and evaluate the prognostic precision of the new one. Materials and Methods: We retrospectively analyzed the records of patients with endometrial cancer that were fully treated in the 1st Department of Obstetrics & Gynecology, in 2012–2023. Patient characteristics, oncological outcome, and follow-up information were collected. The primary outcomes were the stage shifts and the survival data. Results: Sixty-seven (15.5%) patients had a stage shift and the majority of them concerned early-stage disease and specifically an upshift from 2009 stages IA and IB to 2023 stage IIC. Concerning survival, a better median and 5-year PFS was present in stage II disease, and when comparing the prognostic precision of the two FIGO staging systems no significant difference was present. Conclusions: The new 2023 FIGO staging system better distinguishes early-stage endometrial cancer into its prognostic groups and seems to be as precise as the old 2009 FIGO staging system. Full article
(This article belongs to the Special Issue Updates on Endometrial Cancer Screening and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

10 pages, 292 KiB  
Review
HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by Dimitrios Papageorgiou, Galateia Liouta, Ioakeim Sapantzoglou, Eleftherios Zachariou, Dimitra Pliakou, Katerina Papakonstantinou, Theofanis Floros and Evangelia Pliakou
Medicina 2024, 60(12), 2012; https://doi.org/10.3390/medicina60122012 - 6 Dec 2024
Viewed by 1968
Abstract
The most common histological subtypes of endometrial cancer consist of endometrioid and uterine serous carcinoma, with the latter being more aggressive and accompanied by poor prognosis. Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor associated with cell proliferation, [...] Read more.
The most common histological subtypes of endometrial cancer consist of endometrioid and uterine serous carcinoma, with the latter being more aggressive and accompanied by poor prognosis. Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor associated with cell proliferation, differentiation, and survival. HER2 positivity can be diagnosed in many solid tumors. It has been found that approximately one-third of the patients diagnosed with serous carcinoma may overexpress HER2/neu protein and/or show the amplification of the c-erBb2 gene. The prognostic and predictive value of HER2 biomarker is nowadays highlighted and the updates of HER2-directed treatment offer new opportunities for improved efficacy and survival. A number of HER2-targeted therapies have become available in recent years and have had promising results, prompting full drug approvals and additional investigation in many cancer types, among which is endometrial cancer. Data from clinical trials combining classical chemotherapy with anti-HER2 agents, mainly trastuzumab, alone or in combination with pertuzumab, do exist and have been incorporated into international guidelines. Moreover, further research with antibody–drug conjugates and tyrosine kinase inhibitors is being conducted. Acquired resistance remains an important problem, and its underlying mechanisms in endometrial cancer are mostly unknown. Studies exploring earlier use of Her2-directed therapy are also on the way. The purpose of this literature review is to describe the available therapies in the current clinical practice and the most prominent research data regarding the future. In any case, a number of unmet medical needs do exist for HER2-positive serous endometrial cancer, and additional research and studies are warranted to provide further understanding and improved outcomes for this tumor type. Full article
(This article belongs to the Special Issue Updates on Endometrial Cancer Screening and Treatment)

Other

Jump to: Research, Review

14 pages, 980 KiB  
Systematic Review
The Impact of Positive Peritoneal Cytology on the Survival Rates of Early-Stage-Disease Endometrial Cancer Patients: Systematic Review and Meta-Analysis
by Vasilios Pergialiotis, Michail Panagiotopoulos, Antonios Koutras, Andreas Daras, Thomas Ntounis, Michalis Liontos, Georgios Daskalakis and Nikolaos Thomakos
Medicina 2024, 60(5), 733; https://doi.org/10.3390/medicina60050733 - 28 Apr 2024
Cited by 3 | Viewed by 1988
Abstract
Background and Objectives: The impact of positive peritoneal cytology has been a matter of controversy in early-stage endometrial cancer for several years. The latest staging systems do not take into consideration its presence; however, emerging evidence about its potential harmful effect on patient [...] Read more.
Background and Objectives: The impact of positive peritoneal cytology has been a matter of controversy in early-stage endometrial cancer for several years. The latest staging systems do not take into consideration its presence; however, emerging evidence about its potential harmful effect on patient survival outcomes suggests otherwise. In the present systematic review and meta-analysis, we sought to accumulate current evidence. Materials and Methods: Medline, Scopus, the Cochrane Central Register of Controlled Trials CENTRAL, Google Scholar and Clinicaltrials.gov databases were searched for relevant articles. Effect sizes were calculated in Rstudio using the meta function. A sensitivity analysis was carried out to evaluate the possibility of small-study effects and p-hacking. Trial sequential analysis was used to evaluate the adequacy of the sample size. The methodological quality of the included studies was assessed using the Newcastle–Ottawa scale. Results: Fifteen articles were finally included in the present systematic review that involved 19,255 women with early-stage endometrial cancer. The Newcastle–Ottawa scale indicated that the majority of included studies had a moderate risk of bias in their selection of participants, a moderate risk of bias in terms of the comparability of groups (positive peritoneal cytology vs. negative peritoneal cytology) and a low risk of bias concerning the assessment of the outcome. The results of the meta-analysis indicated that women with early-stage endometrial cancer and positive peritoneal cytology had significantly lower 5-year recurrence-free survival (RFS) (hazards ratio (HR) 0.26, 95% CI 0.09, 0.71). As a result of the decreased recurrence-free survival, patients with positive peritoneal cytology also exhibited reduced 5-year overall survival outcomes (HR 0.50, 95% CI 0.27, 0.92). The overall survival of the included patients was considerably higher among those that did not have positive peritoneal cytology (HR 12.76, 95% CI 2.78, 58.51). Conclusions: Positive peritoneal cytology seems to be a negative prognostic indicator of survival outcomes of patients with endometrial cancer. Considering the absence of data related to the molecular profile of patients, further research is needed to evaluate if this factor should be reinstituted in future staging systems. Full article
(This article belongs to the Special Issue Updates on Endometrial Cancer Screening and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop